Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium is the major intracellular cation; it is necessary for the conduction of nerve impulses, maintenance of normal cardiac rhythm, and contraction of skeletal and smooth muscle. Dextrose provides calories and is a source of glucose for cellular metabolism. Sodium chloride provides sodium and chloride ions, maintaining electrolyte balance.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion: 10-20 mEq per hour, not exceeding 40 mEq in 4 hours; maximum 150 mEq per day; dose based on potassium deficit and serum potassium level.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Not applicable for potassium; distribution half-life ~0.5-1 h; elimination depends on renal function; in normal renal function, plasma potassium decline follows biphasic pattern with terminal half-life ~2-4 h.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: >90% as potassium ions; fecal: <10%; minimal biliary elimination.
Category C
Category A/B
Electrolyte
Electrolyte